Pascal Poignard

18.0k total citations · 2 hit papers
69 papers, 6.7k citations indexed

About

Pascal Poignard is a scholar working on Virology, Immunology and Infectious Diseases. According to data from OpenAlex, Pascal Poignard has authored 69 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Virology, 36 papers in Immunology and 28 papers in Infectious Diseases. Recurrent topics in Pascal Poignard's work include HIV Research and Treatment (55 papers), Immune Cell Function and Interaction (28 papers) and Monoclonal and Polyclonal Antibodies Research (20 papers). Pascal Poignard is often cited by papers focused on HIV Research and Treatment (55 papers), Immune Cell Function and Interaction (28 papers) and Monoclonal and Polyclonal Antibodies Research (20 papers). Pascal Poignard collaborates with scholars based in United States, France and United Kingdom. Pascal Poignard's co-authors include Dennis R. Burton, Paul W.H.I. Parren, Ian A. Wilson, Quentin J. Sattentau, Ann J. Hessell, John P. Moore, Eva G. Rakasz, David I. Watkins, Robyn L. Stanfield and Wayne C. Koff and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nature Medicine.

In The Last Decade

Pascal Poignard

66 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Human Circulating PD-1+CXCR3−CXCR5+ Memory Tfh Cells Are Highly Functional and Correlate with Broadly Neutralizing HIV Antibody Responses

2013 625 citations Michela Locci, Colin Havenar‐Daughton et al. Immunity profile →
Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses

2012 316 citations Dennis R. Burton, Pascal Poignard et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pascal Poignard United States	37	5.1k	3.6k	1.9k	1.9k	1.8k	69	6.7k
Gabriela Stiegler United States	36	6.0k 1.2×	3.8k 1.1×	2.3k 1.2×	2.0k 1.1×	2.4k 1.3×	47	7.8k
Miroslaw K. Górny United States	49	5.9k 1.2×	3.7k 1.0×	2.4k 1.3×	2.4k 1.3×	1.8k 1.0×	152	7.2k
Leonidas Stamatatos United States	50	6.2k 1.2×	4.4k 1.2×	2.6k 1.4×	1.8k 1.0×	2.8k 1.6×	132	8.6k
James Arthos United States	45	5.5k 1.1×	4.9k 1.4×	2.1k 1.1×	1.1k 0.6×	1.9k 1.0×	113	8.4k
Georgia D. Tomaras United States	44	4.5k 0.9×	3.7k 1.0×	1.8k 1.0×	987 0.5×	1.5k 0.8×	190	6.4k
Nancy L. Haigwood United States	43	4.6k 0.9×	3.1k 0.9×	2.0k 1.1×	853 0.5×	1.5k 0.8×	133	6.5k
Per Johan Klasse United States	56	6.5k 1.3×	3.9k 1.1×	3.2k 1.7×	2.0k 1.1×	2.6k 1.4×	153	9.4k
Andrés Finzi Canada	42	4.3k 0.8×	2.8k 0.8×	2.5k 1.3×	1.1k 0.6×	1.2k 0.7×	173	5.8k
James Μ. Binley United States	46	7.6k 1.5×	4.3k 1.2×	3.2k 1.7×	2.4k 1.3×	2.2k 1.2×	80	8.8k
Johannes F. Scheid United States	28	3.4k 0.7×	2.8k 0.8×	1.0k 0.5×	1.8k 1.0×	1.7k 0.9×	36	5.0k

Countries citing papers authored by Pascal Poignard

Since Specialization

Citations

This map shows the geographic impact of Pascal Poignard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascal Poignard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascal Poignard more than expected).

Fields of papers citing papers by Pascal Poignard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pascal Poignard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascal Poignard. The network helps show where Pascal Poignard may publish in the future.

Co-authorship network of co-authors of Pascal Poignard

This figure shows the co-authorship network connecting the top 25 collaborators of Pascal Poignard. A scholar is included among the top collaborators of Pascal Poignard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pascal Poignard. Pascal Poignard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Faudry, Éric, Carlos Contreras‐Martel, Isabelle Bally, et al.. (2025). Neutralizing human monoclonal antibodies that target the PcrV component of the Type III Secretion System of Pseudomonas aeruginosa act through distinct mechanisms. eLife.

Fabra-García, Amanda, Judith M. Bolscher, William J. Stone, et al.. (2024). Target-agnostic identification of human antibodies to Plasmodium falciparum sexual forms reveals cross-stage recognition of glutamate-rich repeats. eLife. 13. 2 indexed citations

Bally, Isabelle, Marlyse Buisson, Raphaële Germi, et al.. (2024). Anti-SARS-CoV-2 serology based on ancestral RBD antigens does not correlate with the presence of neutralizing antibodies against Omicron variants. Microbiology Spectrum. 13(1). e0156824–e0156824. 2 indexed citations

Gaymard, Alexandre, Clément Massonnaud, Nathan Peiffer‐Smadja, et al.. (2024). Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial. Journal of Antimicrobial Chemotherapy. 79(11). 2887–2895.

Chabert, Clovis, Anne-Laure Vitte, Domenico Iuso, et al.. (2022). AKR1B10, One of the Triggers of Cytokine Storm in SARS-CoV2 Severe Acute Respiratory Syndrome. International Journal of Molecular Sciences. 23(3). 1911–1911. 11 indexed citations

Hannani, Dalil, Isabelle Bally, Evelyne Gout, et al.. (2022). Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform. Molecular Therapy. 30(5). 1913–1925. 22 indexed citations

Sanjuán, I, Carol Ho-Yan Fong, Juan A. Torreño-Pina, et al.. (2017). Novel in vitro booster vaccination to rapidly generate antigen-specific human monoclonal antibodies. The Journal of Experimental Medicine. 214(8). 2471–2490. 17 indexed citations

Smith, Melissa, Ben Murrell, Kemal Eren, et al.. (2016). Rapid Sequencing of CompleteenvGenes from Primary HIV-1 Samples. Virus Evolution. 2(2). vew018–vew018. 17 indexed citations

McCoy, Laura E., Emilia Falkowska, Katie J. Doores, et al.. (2015). Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies. PLoS Pathogens. 11(8). e1005110–e1005110. 64 indexed citations

10.

Moreau, Alain, Laurence Meyer, Cécile Goujard, et al.. (2014). Adaptation of HIV-1 Envelope Glycoprotein gp120 to Humoral Immunity over the Course of the Epidemic. AIDS Research and Human Retroviruses. 30(S1). A224–A224.

11.

Locci, Michela, Colin Havenar‐Daughton, Elise Landais, et al.. (2013). Human Circulating PD-1+CXCR3−CXCR5+ Memory Tfh Cells Are Highly Functional and Correlate with Broadly Neutralizing HIV Antibody Responses. Immunity. 39(4). 758–769. 625 indexed citations breakdown →

12.

Gach, Johannes S., Heribert Quendler, Tommy Tong, et al.. (2013). A Human Antibody to the CD4 Binding Site of gp120 Capable of Highly Potent but Sporadic Cross Clade Neutralization of Primary HIV-1. PLoS ONE. 8(8). e72054–e72054. 16 indexed citations

13.

Walker, Laura M., Devin Sok, Yoshiaki Nishimura, et al.. (2011). Rapid development of glycan-specific, broad, and potent anti–HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proceedings of the National Academy of Sciences. 108(50). 20125–20129. 60 indexed citations

14.

Hessell, Ann J., Eva G. Rakasz, David M. Tehrani, et al.. (2009). Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIV _Ba-L. Journal of Virology. 84(3). 1302–1313. 250 indexed citations

15.

Venturini, Sara, et al.. (2005). Identification of peptides from human pathogens able to cross‐activate an HIV‐1‐gag‐specific CD4⁺ T cell clone. European Journal of Immunology. 36(1). 27–36. 6 indexed citations

16.

Poignard, Pascal, Rebecca Sabbe, Gastón Picchio, et al.. (1999). Neutralizing Antibodies Have Limited Effects on the Control of Established HIV-1 Infection In Vivo. Immunity. 10(4). 431–438. 184 indexed citations

17.

Koup, Richard A., et al.. (1997). Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design (vol 57, pg 105, 1997). Immunology Letters. 58. 2 indexed citations

18.

Poignard, Pascal, Timothy Fouts, Denise Naniche, John P. Moore, & Quentin J. Sattentau. (1996). Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.. The Journal of Experimental Medicine. 183(2). 473–484. 65 indexed citations

19.

Sattentau, Quentin J., Susan Zolla‐Pazner, & Pascal Poignard. (1995). Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology. 206(1). 713–717. 168 indexed citations

20.

Signoret, Nathalie, Pascal Poignard, Dominique Blanc, & Quentin J. Sattentau. (1993). Human and simian immunodeficiency viruses: virus-receptor interactions. Trends in Microbiology. 1(9). 328–333. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact